Stocks · News reference
Mirum Pharmaceuticals shares are trading higher after the company announced Phase 3 EXPAND data showing LIVMARLI met its primary endpoint and achieved statistical significance across all five prespecified secondary endpoints.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.
8-K filing — Mirum Pharmaceuticals, Inc. (MIRM)
Filed: 2026-10-13 AccNo: 0001759425-26-000051 Size: 181 KB Item 8.01: Other Events
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.